NCT05577585View on ClinicalTrials.gov

Ketamine in OCD: Efficacy and Effects on Stress and Cognition

NARecruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Obsessive-Compulsive DisorderPsychiatric Disorder

Interventions

DRUG

Ketamine 50 MG/ML Blinded

See also Arm description

DRUG

Midazolam

See also Arm description

DRUG

Ketamine 50 MG/ML Open Label

Open Label Follow Up (up to 8 Infusions)

OTHER

Treatment as Usual (TAU)

Treatment as Usual may include psychotherapy, pharmacotherapy, physiotherapy, ergotherapy, or a combination of these-at the discretion of the treating physician, independently of the study.

Trial Locations (1)

1090

RECRUITING

Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna

All Listed Sponsors

lead

Medical University of Vienna

OTHER